Literature DB >> 9691653

[Fulminant Mycoplasma pneumoniae pneumonia resulting in respiratory failure and a prolonged pulmonary lesion].

M Ohmichi1, M Miyazaki, T Ohchi, Y Morikawa, S Tanaka, H Sasaki, Y Hiraga.   

Abstract

A previously healthy 26-year-old woman presented with a fever and coughing on October 1, 1995. Despite treatment with beta-lactam antibiotics at another hospital, she had a high fever, coughing, and dyspnea. A chest roentgenogram showed diffuse infiltrates in both lung fields. On October 9, she was transferred to our hospital. On admission, a chest X-ray film showed marked diffusely infiltrates in both lung fields and a effusion in the left lung. Arterial blood gas analysis after inhalation of 4 liters per minute of oxygen via a nasal cannula revealed a PaO2 of 39.0 torr. Despite treatment with various antibiotics, including minocyclin and gamma-globulin, her respiratory condition rapidly deteriorated. She was mechanically ventilated by with intermittent mandatory ventilation and positive end-experiatory pressure, and received antibiotics and methylprednisolone pulse therapy. He chest X-ray and arterial blood gase findings, gradually improved. The passive hemagglutination titer for Mycoplasma rose from 1:4 on October 9, to 1:2,560 on the 14th hospital day. Acute respiratory failure due to Mycoplasma pneumoniae pneumonia was diagnosed. A chest X-ray film obtained 2 months after admission showed linear-reticular shadows in both lung fields and pulmonary-function tests revealed abnormally low vital capacity and diffusing capacity. Examination of a specimen obtained by transbronchial lung biopsy revealed focal intraalveolar exudate with fibrin and macrophages. Very mild interstitial thickening was also noted. The lymphocyte stimulation responses to PPD, PHA, and Con A were low early in the illness and became normal after recovery. Several reports have said that an enhanced pulmonary cellular immune response may be responsible for the development of severe Mycoplasma pneumoniae, resulting in a temporary decrease in the cell-mediated immune response. This case supports that hypothesis. We believe that in severe cases, steroid therapy including pulse therapy should be started as soon as possible.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9691653

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  3 in total

1.  Identification of a mechanism for lung inflammation caused by Mycoplasma pneumoniae using a novel mouse model.

Authors:  Takeshi Saraya; Koh Nakata; Kazuhide Nakagaki; Natsuki Motoi; Kuniko Iihara; Yasunori Fujioka; Teruaki Oka; Daisuke Kurai; Hiroo Wada; Haruyuki Ishii; Haruhiko Taguchi; Shigeru Kamiya; Hajime Goto
Journal:  Results Immunol       Date:  2011-11-11

Review 2.  Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications.

Authors:  Takeshi Saraya; Daisuke Kurai; Kazuhide Nakagaki; Yoshiko Sasaki; Shoichi Niwa; Hiroyuki Tsukagoshi; Hiroki Nunokawa; Kosuke Ohkuma; Naoki Tsujimoto; Susumu Hirao; Hiroo Wada; Haruyuki Ishii; Koh Nakata; Hirokazu Kimura; Kunihisa Kozawa; Hajime Takizawa; Hajime Goto
Journal:  Front Microbiol       Date:  2014-08-11       Impact factor: 5.640

Review 3.  Mycoplasma pneumoniae infection: Basics.

Authors:  Takeshi Saraya
Journal:  J Gen Fam Med       Date:  2017-04-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.